| Mercy Home Health | |
| 4401 W Memorial, Suite 143, Oklahoma City, Oklahoma 73134 | |
| (405) 486-8600 | |
| Name | Mercy Home Health |
|---|---|
| Location | 4401 W Memorial, Suite 143, Oklahoma City, Oklahoma |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 377048 |
| Ownership Type | Voluntary Non Profit - Religious Affiliation |
| Service Area Zip Codes | 73003, 73007, 73008, 73009, 73010, 73012, 73013, 73014, 73016, 73019, 73020, 73025, 73026, 73027, 73028, 73034, 73036, 73040, 73044, 73045, 73047, 73049, 73054, 73056, 73058, 73059, 73064, 73065, 73066, 73068, 73069, 73070, 73071, 73072, 73078, 73083, 73084, 73089, 73090, 73099, 73103, 73104, 73105, 73106, 73107, 73108, 73109, 73110, 73111, 73112, 73114, 73115, 73116, 73117, 73118, 73119, 73120, 73121, 73122, 73127, 73128, 73129, 73130, 73131, 73132, 73134, 73135, 73139, 73140, 73141, 73142, 73149, 73150, 73152, 73156, 73157, 73159, 73160, 73162, 73165, 73169, 73170, 73173, 73179, 73195, 73750, 73756, 73762, 73772, 74801, 74804, 74832, 74834, 74851, 74855, 74857, 74881 |
| NPI Number | 1437256070 |
| Organization Name | MERCY HOSPITAL OKLAHOMA CITY, INC. |
| Doing Business As | MERCY HOME HEALTH |
| Address | 4401 W Memorial Rd Ste 143, Oklahoma City, OK 73134 |
| Phone Number | 405-486-8600 |
News Archive
Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The discovery in common brewer's yeast of a new, infectious, misfolded protein - or prion - by University of Illinois at Chicago molecular biologists raises new questions about the roles played by these curious molecules, often associated with degenerative brain diseases like "mad cow" and its human counterpart, Creutzfeldt-Jakob.
Mologic Ltd, a developer of powerful, personalized diagnostics to improve the lives of patients, today announced that it has commenced a clinical trial to evaluate the Company's urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis patients.
› Verified 1 days ago
| Quality Rating: |
News Archive
Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The discovery in common brewer's yeast of a new, infectious, misfolded protein - or prion - by University of Illinois at Chicago molecular biologists raises new questions about the roles played by these curious molecules, often associated with degenerative brain diseases like "mad cow" and its human counterpart, Creutzfeldt-Jakob.
Mologic Ltd, a developer of powerful, personalized diagnostics to improve the lives of patients, today announced that it has commenced a clinical trial to evaluate the Company's urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis patients.
› Verified 1 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 97 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99.5 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.9 | 99.6 |
| How often the home health team checked patients for depression | 99.1 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 85.2 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 94.9 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 95 | 96.4 |
News Archive
Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The discovery in common brewer's yeast of a new, infectious, misfolded protein - or prion - by University of Illinois at Chicago molecular biologists raises new questions about the roles played by these curious molecules, often associated with degenerative brain diseases like "mad cow" and its human counterpart, Creutzfeldt-Jakob.
Mologic Ltd, a developer of powerful, personalized diagnostics to improve the lives of patients, today announced that it has commenced a clinical trial to evaluate the Company's urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis patients.
› Verified 1 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 71.8 | 79.6 |
| How often patients got better at getting in and out of bed | 66.6 | 81.1 |
| How often patients got better at bathing | 73.7 | 82.3 |
| How often patients’ breathing improved | 63 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 94.4 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 60.5 | 75 |
| How often home health patients had to be admitted to the hospital | 14.2 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 17.4 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 98.2 | 94 |
News Archive
Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The discovery in common brewer's yeast of a new, infectious, misfolded protein - or prion - by University of Illinois at Chicago molecular biologists raises new questions about the roles played by these curious molecules, often associated with degenerative brain diseases like "mad cow" and its human counterpart, Creutzfeldt-Jakob.
Mologic Ltd, a developer of powerful, personalized diagnostics to improve the lives of patients, today announced that it has commenced a clinical trial to evaluate the Company's urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis patients.
› Verified 1 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The discovery in common brewer's yeast of a new, infectious, misfolded protein - or prion - by University of Illinois at Chicago molecular biologists raises new questions about the roles played by these curious molecules, often associated with degenerative brain diseases like "mad cow" and its human counterpart, Creutzfeldt-Jakob.
Mologic Ltd, a developer of powerful, personalized diagnostics to improve the lives of patients, today announced that it has commenced a clinical trial to evaluate the Company's urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis patients.
› Verified 1 days ago
The patient survey data of Mercy Home Health is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 91 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 86 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 85 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 89 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 87 | 78 |
News Archive
Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The discovery in common brewer's yeast of a new, infectious, misfolded protein - or prion - by University of Illinois at Chicago molecular biologists raises new questions about the roles played by these curious molecules, often associated with degenerative brain diseases like "mad cow" and its human counterpart, Creutzfeldt-Jakob.
Mologic Ltd, a developer of powerful, personalized diagnostics to improve the lives of patients, today announced that it has commenced a clinical trial to evaluate the Company's urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis patients.
› Verified 1 days ago
Ssm Health At Home Home Health - Oklahoma Location: 608 Nw 9th Street, Suite 6200, Oklahoma City, Oklahoma 73103 Ratings: Phone: (405) 231-2992 | |
Mercy Home Health Location: 4401 W Memorial, Suite 143, Oklahoma City, Oklahoma 73134 Ratings: Phone: (405) 486-8600 | |
Integris Home Care Oklahoma City Location: 3500 N W 56th Street, Ste 201, Oklahoma City, Oklahoma 73112 Ratings: Phone: (405) 951-8400 | |
Alliance Oklahoma Home Health Okc Location: 7919 Mid America Blvd, Suite 200, Oklahoma City, Oklahoma 73135 Ratings: Phone: (405) 736-0064 | |
Angels Care Home Health Of Oklahoma Location: 4045 Nw 64th Street, Suite 150, Oklahoma City, Oklahoma 73116 Ratings: Phone: (405) 767-9555 | |
Carter Healthcare Of Central Oklahoma, Llc Location: 3104 South Lakeside Drive, Oklahoma City, Oklahoma 73119 Ratings: Phone: (405) 947-7700 |